Avidity Biosciences Director Sells $3.8M in Stock
Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
- Latest
- Trending
Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
Amazon.com Inc (NASDAQ:) and Sunshine Biopharma Inc (NASDAQ:) were the worst performers, while American Express Company (NYSE:) and Top Wealth ...
Consider investing in AbbVie and e.l.f., two names with significant growth potential in 2024. AbbVie shines as a quality business ...
Explore the intriguing stock volatility of Japer Therapeutics on NASDAQ as it experiences notable fluctuations, urging investors to delve deeper ...
Delve into a comprehensive financial analysis of Cabaletta Bio Inc, a key player in the NASDAQ exchange, with a strong ...
Fortress Biotech's Q3 earnings per share of -53 cents exceeded the analyst estimate of -$1.97 while revenue of $19.95 million ...
Fortress Biotech Inc's shares dropped 27.9% this quarter, exceeding analysts' predicted loss of $1.97 per share.
Discover the financial insights of Dermira, a biopharmaceutical company, and gain a deeper understanding of their stock performance and market ...
Moleculin Biotech's stock has been given a "sell" rating by a firm, with a 1-year low of $4.34 and a ...
Atticus Wealth Management LLC buys stake in Moleculin Biotech as the firm sets a “sell” rating on the stock; MBRX ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.